Evidence map›Paper›PMID 40525248›Full record

SynthesisTechnology in cancer research & treatment

Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Combination with Chemotherapy for Advanced Breast Cancer: A Systematic Review and Meta-Analysis.

Qiuhua Duan, Yue Feng, Lichen Cao, Lijun Hu, Jianlin Wang, Fei Sun, Qinghong Meng, Mengyun Zhou, Jingping Yu, Haiyan Gao

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qiuhua DuanDepartment of Oncology, Nanchuan Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0003-1762-0807
Yue FengDepartment of Radiation Oncology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0003-0795-6139
Lichen CaoDepartment of Breast Surgery, Fourth People's Hospital of Changzhou, Changzhou, China.ORCID 0000-0002-4454-0178
Lijun HuDepartment of Radiation Oncology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Jianlin WangDepartment of Radiation Oncology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Fei SunDepartment of Radiation Oncology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Qinghong MengDepartment of Radiation Oncology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Mengyun ZhouDepartment of Radiation Oncology, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou, China.
Jingping YuDepartment of Radiation Oncology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.ORCID 0000-0003-4383-6222
Haiyan GaoDepartment of Breast Surgery, Fourth People's Hospital of Changzhou, Changzhou, China.ORCID 0000-0003-1405-4336

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PurposeTo comprehensively evaluate the efficacy and safety of combining poly (ADP-ribose) polymerase (PARP) inhibitors with chemotherapy in patients with advanced breast cancer.MethodsA systematic literature search was conducted in PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov to identify randomized controlled trials (RCTs) evaluating PARP inhibitor-chemotherapy combinations. Studies reporting progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and safety outcomes were included. Data extraction and quality assessment were performed independently by two reviewers, and a meta-analysis was conducted using random-effects models.ResultsOf 970 studies retrieved, four RCTs involving 1064 patients met the inclusion criteria. PARP inhibitors combined with chemotherapy significantly improved PFS (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.63-0.84,

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsFemaleHumansNeoplasm StagingRandomized Controlled Trials as TopicTreatment OutcomePoly(ADP-ribose) Polymerase Inhibitorsadvanced breast cancerBRCA mutedchemotherapymeta-analysisPARP inhibitortriple-negative breast cancer

Identifiers

PMID40525248
PMCPMC12174678

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.